公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
公司地址 85 Dan Road, Canton, MA, USA, 02021
電話號碼 +1 781 575-0775
傳真號碼 +1 781 575-1570
公司網頁 https://www.organogenesis.com
員工數量 854
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Lori Freedman Chief Administrative and Legal Officer 美元 499.38K 12/05/2025
Mr. Robert Cavorsi Vice President, Strategy -- 12/05/2025
Mr. Patrick McGuire Chief Accounting Officer -- 23/02/2026
Mr. David C. Francisco Chief Financial Officer 美元 469.27K 23/02/2026
Mr. Gary S. Gillheeney, Sr Chairman of the Board, President and Chief Executive Officer 美元 942.51K 26/02/2026
Mr. Patrick Bilbo Chief Operating Officer 美元 489.30K 12/05/2025
Mr. Brian Grow Chief Commercial Officer 美元 463.80K 12/05/2025
Mr. Antonio S. Montecalvo Vice President, Health Policy -- 12/05/2025
 
董事會成員
董事會 職務 更新日期
Mr. Glenn H. Nussdorf Director 26/02/2026
Mr. Garrett Lustig Independent Director 26/02/2026
Mr. Gilberto Quintero Independent Director 26/02/2026
Dr. Michael Joseph Driscoll Independent Director 26/02/2026
Mr. David Erani Director 12/05/2025
Mr. Robert Ades Director 26/02/2026
Mr. Gary S. Gillheeney, Sr Chairman of the Board, President and Chief Executive Officer 26/02/2026
Mr. Alan A. Ades Director 12/05/2025
Ms. Prathyusha Duraibabu Independent Director 26/02/2026
Ms. Michele Korfin Independent Director 26/02/2026
Mr. Jon L. Giacomin Independent Director 26/02/2026
Mr. Arthur S. Leibowitz Lead Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 03:32)
代號 名稱 佔比% 持有日期
DCORDimensional US Core Equity 1 ETF0.01%27/02/2026
LITLSimplify Piper Sandler USSm-CpPLUSIncETF0.01%27/02/2026
DFUSDimensional US Equity Market ETF0.01%27/02/2026
AVUSAvantis US Equity ETF0.01%28/02/2026
FLQSFranklin US Small Cap Mltfctr Idx ETF0.01%28/02/2026
VTHRVanguard Russell 3000 ETF0.004%31/01/2026
DXUVDimensional US Vector Equity ETF0.004%27/02/2026
UWMProShares Ultra Russell20000.003%27/02/2026
URTYProShares UltraPro Russell20000.003%27/02/2026
ITWOProShares Russell 2000 High Income ETF0.002%27/02/2026
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.002%28/02/2026
AVTMAvantis Total Equity Markets ETF0.002%28/02/2026
QSMLWisdomTree U.S. Small Cap Quality Gr0.001%27/02/2026
GUGGuggenheim Active Allocation Fund0.0003%30/11/2025
PBSMInvesco PureBeta MSCI USA Small Cap ETF0.0002%31/05/2023
HDGProShares Hedge Replication0.0001%27/02/2026
AOMiShares Core 40/60 Moderate Allc ETF<0.000001%27/02/2026
DWASInvesco Dorsey Wright SmallCap Momt ETF<0.000001%01/07/2025
ESSCEventide Small Cap ETF<0.000001%06/02/2026
EWSCInvesco S&P SmallCap 600® Equal Wt ETF<0.000001%20/03/2023
  1   2    3  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.